Cargando…
Relapse of Eosinophilic Esophagitis on Dupilumab
Dupilumab is approved for the treatment of eosinophilic esophagitis (EoE). We report a teenager with difficult-to-treat EoE on topical corticosteroids (TS) who achieved clinical and histological remission when initiated on dupilumab for a primary indication of atopic dermatitis. However, when his TS...
Autores principales: | Buendia, Matthew A., Choksi, Yash A., Hiremath, Girish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158342/ https://www.ncbi.nlm.nih.gov/pubmed/37168482 http://dx.doi.org/10.1097/PG9.0000000000000273 |
Ejemplares similares
-
Microbiome in Eosinophilic Esophagitis—Metagenomic, Metatranscriptomic, and Metabolomic Changes: A Systematic Review
por: Busing, Jordan D., et al.
Publicado: (2021) -
Refractory Pediatric Fibrostenotic Eosinophilic Esophagitis Treated With Dupilumab
por: Gangadharan Nambiar, Gopinathan, et al.
Publicado: (2022) -
Eosinophils Exert Antitumorigenic Effects in the Development of Esophageal Squamous Cell Carcinoma
por: Jacobse, Justin, et al.
Publicado: (2023) -
Eosinophilic granulomatosis with polyangiitis after treatment with dupilumab
por: Yamazaki, Kai, et al.
Publicado: (2022) -
Eosinophilic Gastritis in a Patient Previously Treated with Dupilumab
por: Iwamuro, Masaya, et al.
Publicado: (2020)